News

February 6, 2012 - Visionary Pharmaceuticals presents research results on small molecule RORgamma modulators at the TH17 Cells in Health and Disease Conference at Keystone, Colorado.  Click here to see the poster.

January 24, 2012 - Visionary Pharmaceuticals has filed a Provisional Application for "Novel Triterpene Compounds, Compositions and Uses Thereof" for therapeutic treatment of an Orphan autoimmune disease.

January 9 - 12, 2012 - Visionary Pharmaceuticals attends the JP Morgan Global Healthcare Conference 2012 in San Francisco, California.

September 7, 2011 - Visionary Pharmaceuticals is a 2011 Finalist for the San Diego Tech Coast Angels Quickpitch Investor Event on October 6, 2011.

July 27, 2011 -  PR Newswire press release for Visionary Pharmaceuticals Seed Round Financing.  Press Release

July 26, 2011 - Dushyant Pathak, PhD, MBA President of VentureEdge, LLC joins the Board of Directors.

July 25, 2011 – Visionary Pharmaceuticals launches full-scale TH17 cell directed drug discovery activities.

July 1, 2011 – Visionary moves into a state-of-the-art laboratory facility located in Biotech Beach (San Diego). Facilities include cell and biochemical screening bays and BSL2 mammalian tissue culture labs.

June 21, 2011 – Visionary Pharmaceuticals opens Seed Financing investment round.

May 22, 2011 – Visionary Pharmaceuticals purchases a collection of laboratory capital equipment to perform advanced inflammation and cancer cell screening.

February 28, 2011 – Jennifer McAlpine, PhD, joins Visionary Pharmaceuticals as Head of Project Management.

January 5, 2011 – Louis Tommasino, CPA, joins Visionary Pharmaceuticals as acting CFO.

November 17, 2010 – David W. Anderson, PhD, former CSO/VP of Research at Proprius joins the Scientific Advisory Board.

October 21, 2010 – John K. Westwick, PhD, President and CEO of OdysseyThera joins the Scientific Advisory Board.

July 14, 2010 – Visionary Pharmaceuticals incorporates as a Delaware S Corporation.

News & Events